Logo image of IMGN

ImmunoGen Inc (IMGN) Stock Fundamental Analysis

NASDAQ:IMGN - Nasdaq - US45253H1014 - Common Stock - Currency: USD

31.23  0 (0%)

After market: 31.24 +0.01 (+0.03%)

Fundamental Rating

3

Overall IMGN gets a fundamental rating of 3 out of 10. We evaluated IMGN against 560 industry peers in the Biotechnology industry. The financial health of IMGN is average, but there are quite some concerns on its profitability. IMGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IMGN had negative earnings in the past year.
IMGN had a negative operating cash flow in the past year.
IMGN had negative earnings in each of the past 5 years.
In the past 5 years IMGN always reported negative operating cash flow.
IMGN Yearly Net Income VS EBIT VS OCF VS FCFIMGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.94%, IMGN belongs to the top of the industry, outperforming 89.06% of the companies in the same industry.
IMGN's Return On Equity of -13.09% is amongst the best of the industry. IMGN outperforms 89.06% of its industry peers.
Industry RankSector Rank
ROA -8.94%
ROE -13.09%
ROIC N/A
ROA(3y)-34.29%
ROA(5y)-40.85%
ROE(3y)-78.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMGN Yearly ROA, ROE, ROICIMGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K -1.5K

1.3 Margins

With an excellent Gross Margin value of 98.61%, IMGN belongs to the best of the industry, outperforming 98.32% of the companies in the same industry.
IMGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMGN Yearly Profit, Operating, Gross MarginsIMGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

IMGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMGN has been increased compared to 1 year ago.
Compared to 1 year ago, IMGN has a worse debt to assets ratio.
IMGN Yearly Shares OutstandingIMGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
IMGN Yearly Total Debt VS Total AssetsIMGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

IMGN has an Altman-Z score of 18.14. This indicates that IMGN is financially healthy and has little risk of bankruptcy at the moment.
IMGN has a better Altman-Z score (18.14) than 90.91% of its industry peers.
IMGN has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.16, IMGN is not doing good in the industry: 68.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 18.14
ROIC/WACCN/A
WACC11.02%
IMGN Yearly LT Debt VS Equity VS FCFIMGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M -200M 300M

2.3 Liquidity

IMGN has a Current Ratio of 5.69. This indicates that IMGN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.69, IMGN perfoms like the industry average, outperforming 56.57% of the companies in the same industry.
IMGN has a Quick Ratio of 5.65. This indicates that IMGN is financially healthy and has no problem in meeting its short term obligations.
IMGN has a Quick ratio (5.65) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.69
Quick Ratio 5.65
IMGN Yearly Current Assets VS Current LiabilitesIMGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

IMGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.20%, which is quite impressive.
Looking at the last year, IMGN shows a very strong growth in Revenue. The Revenue has grown by 200.63%.
IMGN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.17% yearly.
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.26%
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y-1.17%
Sales Q2Q%636.36%

3.2 Future

Based on estimates for the next years, IMGN will show a very strong growth in Earnings Per Share. The EPS will grow by 32.99% on average per year.
IMGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 69.78% yearly.
EPS Next Y108.78%
EPS Next 2Y56.06%
EPS Next 3Y44.14%
EPS Next 5Y32.99%
Revenue Next Year344.16%
Revenue Next 2Y154.65%
Revenue Next 3Y109.41%
Revenue Next 5Y69.78%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMGN Yearly Revenue VS EstimatesIMGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B
IMGN Yearly EPS VS EstimatesIMGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

IMGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 81.49, the valuation of IMGN can be described as expensive.
Based on the Price/Forward Earnings ratio, IMGN is valued cheaper than 93.94% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.13. IMGN is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 81.49
IMGN Price Earnings VS Forward Price EarningsIMGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMGN Per share dataIMGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

IMGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as IMGN's earnings are expected to grow with 44.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.06%
EPS Next 3Y44.14%

More info and screens

0

5. Dividend

5.1 Amount

IMGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ImmunoGen Inc

NASDAQ:IMGN (2/9/2024, 8:00:02 PM)

After market: 31.24 +0.01 (+0.03%)

31.23

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-09 2024-02-09/amc
Earnings (Next)04-26 2024-04-26/amc
Inst Owners0.16%
Inst Owner Change0%
Ins Owners0.43%
Ins Owner Change0%
Market Cap8.72B
Analysts70.53
Price Target31.69 (1.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)102.82%
Min EPS beat(2)85.91%
Max EPS beat(2)119.72%
EPS beat(4)4
Avg EPS beat(4)66.67%
Min EPS beat(4)23.99%
Max EPS beat(4)119.72%
EPS beat(8)6
Avg EPS beat(8)47.51%
EPS beat(12)10
Avg EPS beat(12)59.04%
EPS beat(16)13
Avg EPS beat(16)56.88%
Revenue beat(2)2
Avg Revenue beat(2)36.59%
Min Revenue beat(2)4.48%
Max Revenue beat(2)68.71%
Revenue beat(4)4
Avg Revenue beat(4)86.57%
Min Revenue beat(4)4.48%
Max Revenue beat(4)138.97%
Revenue beat(8)7
Avg Revenue beat(8)54.29%
Revenue beat(12)8
Avg Revenue beat(12)38.51%
Revenue beat(16)11
Avg Revenue beat(16)32.28%
PT rev (1m)0.02%
PT rev (3m)34.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.27%
EPS NY rev (1m)6.14%
EPS NY rev (3m)223.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.12%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)7.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 81.49
P/S 30.32
P/FCF N/A
P/OCF N/A
P/B 15.53
P/tB 15.53
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.38
Fwd EY1.23%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS1.03
BVpS2.01
TBVpS2.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.94%
ROE -13.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.61%
FCFM N/A
ROA(3y)-34.29%
ROA(5y)-40.85%
ROE(3y)-78.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 109.3%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.69
Quick Ratio 5.65
Altman-Z 18.14
F-Score4
WACC11.02%
ROIC/WACCN/A
Cap/Depr(3y)63.67%
Cap/Depr(5y)66.52%
Cap/Sales(3y)1.33%
Cap/Sales(5y)3.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.26%
EPS Next Y108.78%
EPS Next 2Y56.06%
EPS Next 3Y44.14%
EPS Next 5Y32.99%
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y-1.17%
Sales Q2Q%636.36%
Revenue Next Year344.16%
Revenue Next 2Y154.65%
Revenue Next 3Y109.41%
Revenue Next 5Y69.78%
EBIT growth 1Y59.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.66%
EBIT Next 3Y43.02%
EBIT Next 5Y35.85%
FCF growth 1Y-71.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.08%
OCF growth 3YN/A
OCF growth 5YN/A